Dr. Geynisman on Sequencing of Agents for Kidney Cancer

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses challenges facing the sequencing of agents for patients with metastatic kidney cancer.

Currently, tyrosine kinase inhibitors (TKIs) are given first, followed by drugs such as nivolumab (Opdivo), cabozantinib (Cabometyx), and lenvatinib (Lenvima) plus everolimus (Afinitor), states Geynisman.

Every patient is unique and has different needs and comorbidities. There are a number of options so determining treatment depends on the patient.